Autoimmune Diseases
From the Journals
List of medications linked to drug-induced lupus expands
A new data-mining study adds 42 new drugs.
Conference Coverage
New findings raise questions about the role of ANAs in SLE
Studies suggest that 20%-30% of SLE patients are ANA negative at testing and that there is a great deal of variability across tests, which could...
Conference Coverage
Novel SSc classification scheme aims to improve risk stratification
CHICAGO – The scheme combines autoantibody specificity and extent of skin involvement.
From the Journals
Increased cancer risk in dermatomyositis has temporal limits
Conference Coverage
Combination immunotherapy ups survival in ILD patients with anti-MDA5–positive dermatomyositis
But cytomegalovirus reactivation and other opportunistic infections must be monitored.
Conference Coverage
RELIEF: In Behçet’s, apremilast improves oral ulcers for up to 28 weeks
Apremilast was safe and effective for treating oral ulcers in patients with Behçet’s disease in a phase 3 study
Conference Coverage
Three drugs disappoint in SSc trials, but show some promise
CHICAGO – Recent randomized, placebo-controlled, phase 3 trials of tocilizumab, abatacept, and riociguat for the...
Feature
ACR CRISS: A way forward for scleroderma treatment trials?
From the Journals
Short-term lung function better predicts mortality risk in SSc
Surrogate measures of lung disease progression may help to determine the need for early intervention.
Conference Coverage
Development of reversible B-cell inhibitor XmAb5871 for SLE moves forward
Conference Coverage
Fear of blindness hobbles hydroxychloroquine treatment of SLE